⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469732 | 0.79 | CA2 (0.37) | — | |
| SCHEMBL17456574 | 0.77 | CA2 (0.35) | — | |
| SCHEMBL28694069 | 0.74 | — | — | |
| SCHEMBL5558118 | 0.74 | — | — | |
| Methane SCHEMBL25300596 | 0.72 | — | — | |
| SCHEMBL17456474 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL5462398 | 0.72 | — | — | |
| SCHEMBL17456423 | 0.72 | — | — | |
| SCHEMBL10555015 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL15720234 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3033343-B1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2018-12-05 | — | — | EP | claimed |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-29 | — | — | US | claimed |
| EP-3033343-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | Novartis AG (CH) | 2016-06-22 | — | — | EP | claimed |
| US-20160136150-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2016-05-19 | — | — | US | claimed |
| US-9227969-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | claimed |
| WO-2015022662-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2015-02-19 | — | — | WO | claimed |
| US-20150051209-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-1038880-B1 | Androstanes and pregnanes for allosteric modulation of GABA receptor | EURO CELTIQUE SA (LU) | 2007-10-17 | — | — | EP | claimed |
| US-6143736-A | USED TO ALLEVIATE STRESS, ANXIETY, SEIZURES, MOOD DISORDERS, PREMENSTRUAL SYNDROME(PMS) AND POSTNATAL DEPRESSION (PND AND TO INDUCE ANESTHESIA | COCENSYS, INC. (US) | 2000-11-07 | — | — | US | claimed |
| EP-1038880-A2 | Androstanes and pregnanes for allosteric modulation of GABA receptor | COCENSYS, INC. (US) | 2000-09-27 | — | — | EP | claimed |
| EP-0752860-A4 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS INC (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0752860-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1997-01-15 | — | — | EP | claimed |
| WO-1995021617-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1995-08-17 | — | — | WO | claimed |
| EP-3033343-B1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2018-12-05 | — | — | EP | disclosed |
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2018-07-03 | — | — | US | disclosed |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-29 | — | — | US | disclosed |
| US-4863903-A | RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |